HCPLive staff

Study results show significant regional variations in the types of procedures and tests administered and the number of prescriptions written for patients with irritable bowel syndrome (IBS), as well as in the number of emergency department visits and hospital admissions.

In the era of rapidly improving cure rates for hepatitis C infection, has the importance of staging as part of treatment diminished?

Interim study results presented at ACG 2014 indicate that treatment with vedolizumab safely and effectively maintains long-term clinical remission and response in patients with Crohn's disease and ulcerative colitis.

Pirfenidone has been approved in Europe for the treatment of idiopathic pulmonary fibrosis (IPF) since 2011, whereas this is the first approval for nintedanib for the treatment of IPF.

Online system that allows preschools and child care centers to report illnesses to local public health departments could improve the detection of disease outbreaks and allow resources to be mobilized more quickly.

A nurse at Texas Health Presbyterian Hospital who provided care for the Ebola patient hospitalized there has tested positive for Ebola in a preliminary test.

At IDWeek 2014, one of the physicians from the admitting hospital reviewed the facts of the case, outlined the testing strategy utilized during the epidemiologic investigation into the causes of the paralysis, discussed possible factors suggesting an association with EV-D68, and provided an update on the prognosis of the affected children.

Pediatricians' approach to discussing and recommending HPV vaccination with parents and adolescents varies widely, and can have a significant impact on parents' decision to vaccinate.

In treatment-naive patients with genotype 4 HCV, treatment with daclatasvir in combination with peginterferon alfa/ribavirin resulted in higher SVR12 rates than treatment with peginterferon alfa/ribavirin alone.

Results from a study of herpes zoster incidence following periods of acute stress in a large cohort of patients suggest the conventional wisdom on this subject may be wrong.

The majority of patients with psoriatic arthritis treated with disease-modifying antirheumatic drugs will switch medications, discontinue treatment, or add an additional medicine, usually within a few months of initiating treatment.

Allergan's Ozurdex (dexamethasone intravitreal implant) 0.7 mg is now approved for use in the general diabetic macular edema patient population.

The Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus Network is a public-private partnership designed to accelerate research into more effective diagnostic and treatment approaches for these autoimmune diseases.

Otezla (apremilast) is an oral, selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.

Results from a 12-week study show that treatment with once-daily, single-entity hydrocodone formulated with abuse-deterrent properties is safe and effective compared with placebo.

Study results show that patients diagnosed with fibromyalgia often discontinue treatment. Those that do not frequently augment their initial treatment regimen with one or more additional medications, including some that are not recommended by current guidelines.

The patient-reported painDETECT questionnaire has been shown to accurately and reliably identify neuropathic pain across a range of conditions.

Trulicity (dulaglutide) is a once-weekly subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.

Stendra (avanafil) is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.

Researchers have developed a math model that can accurately predict the progression from nephritis to interstitial fibrosis in patients with systemic lupus erythematosus.

Movantik (naloxegol), an oral peripherally acting mu-opioid receptor antagonist, has been approved by the FDA for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) is a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.

Clinicians who treat patients suffering with osteoarthritis pain have a new low-dose nonsteroidal anti-inflammatory drug (NSAID) option at their disposal. Zorvolex (diclofenac) was developed to meet prevailing FDA recommendations regarding NSAID dosing and treatment duration.

Eliquis is also now indicated for reducing the risk of recurrent DVT and PE following initial therapy.

Belsomra (suvorexant) is the first orexin receptor antagonist approved for insomnia.

Fixed-dose tablet is the first sodium glucose cotransporter 2 (SGLT2) inhibitor plus metformin combo product to receive approval in the US.

Orbactiv (oritavancin) is a new antibacterial drug approved to treat patients with acute bacterial skin and skin structure infections.

Patients with osteoporosis got some good news at a recent conference when the results of a study showed that taking the drug denosumab can help increase bone density and keep their rate of fractures at a low level.

A new pill could be the next tool in a patient's fight to lose weight, according to a recent study.

Obese and overweight patients who were treated with the drug liraglutide experienced significant weight loss and were less likely to develop type 2 diabetes than patients who received placebo.